8-K: Disc Medicine Q3 2025: Bitopertin NDA & Cash Runway Extended

Disc Medicine reports Q3 2025 financial results, highlights bitopertin NDA submission with FDA priority voucher, and extends cash runway into 2029.

Summary

• Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025.
• Awarded the FDA Commissioners National Priority Voucher (CNPV), which is designed to shorten the expected NDA review period to 1-2 months from NDA acceptance.
• Anticipates potential US approval and launch of bitopertin for EPP in late 2025 or early 2026.
• Initial data from the Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) will be presented at the American Society of Hematology (ASH) conference in December.
• Progressing the ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and initiated a Phase 1b study of DISC-3405 in sickle cell disease (SCD) in October 2025.
• Ended Q3 2025 with approximately $615.9 million in cash, cash equivalents, and marketable securities.
• Completed a public offering in October 2025, with net proceeds of approximately $211 million, expected to extend the cash runway into 2029.
• Net loss for the three months ended September 30, 2025, was $62.3 million, compared to $26.6 million for the same period in 2024.
• Research and Development (R&D) expenses were $50.3 million for Q3 2025, up from $24.7 million for Q3 2024.
• Selling, General and Administrative (SG&A) expenses were $17.4 million for Q3 2025, up from $8.2 million for Q3 2024.

Sentiment

Score: 8

Explanation: The filing presents strong positive developments with the NDA submission for bitopertin and the receipt of an FDA priority review voucher, significantly de-risking the lead program and accelerating potential market entry. The successful capital raise extending the cash runway into 2029 provides substantial financial stability. While operating expenses and net loss increased, this is expected for a company advancing multiple clinical programs and preparing for commercialization. The mixed results for DISC-0974 in NDD-CKD are a minor setback but do not overshadow the overall positive progress.

Positives

• Submitted NDA for bitopertin in EPP seeking priority review and accelerated approval.
• Received the FDA Commissioners National Priority Voucher (CNPV), which is designed to shorten the NDA review process to 1-2 months from NDA acceptance.
• Accelerating activities to support a potential US approval and launch of bitopertin in late 2025 or early 2026.
• Strong financial position ending Q3 2025 with approximately $615.9 million in cash, cash equivalents, and marketable securities.
• Completed a public offering in October 2025, raising approximately $211 million in net proceeds.
• Extended cash runway into 2029, providing significant financial stability.
• Pipeline progressing well with initial data from Phase 2 study of DISC-0974 in MF anemia to be presented at ASH in December.
• Initiated Phase 1b study of DISC-3405 in sickle cell disease (SCD) in October 2025.

Negatives

• Net loss significantly increased to $62.3 million for Q3 2025, compared to $26.6 million for Q3 2024.
• Research and Development expenses more than doubled to $50.3 million for Q3 2025, from $24.7 million for Q3 2024.
• Selling, General and Administrative expenses more than doubled to $17.4 million for Q3 2025, from $8.2 million for Q3 2024.
• Meaningful hemoglobin increases observed in only a subset of patients in the Phase 1b study of DISC-0974 in NDD-CKD, leading Disc to assess options for the program.

Risks

• The adequacy of Disc's capital to support its future operations and its ability to successfully initiate and complete clinical trials.
• The difficulty in predicting the time and cost of development of Disc's product candidates.
• The timing of initiation of Disc's planned preclinical studies and clinical trials.
• The timing of the availability of data from Disc's clinical trials.
• Disc's ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases.
• The risk that the results of Disc's preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval.
• The content and timing of decisions made by the FDA and other regulatory authorities.
• Other risks and uncertainties described in Disc's filings with the Securities and Exchange Commission, including in the Risk Factors section of Disc's Annual Report on Form 10-K for the year ended December 31, 2024, and in subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Disc Medicine expects potential US approval and launch of bitopertin for EPP in late 2025 or early 2026, with the FDA Commissioners National Priority Voucher potentially shortening the review period. Initial data for DISC-0974 in MF anemia is anticipated in December, and data for DISC-3405 in PV and SCD are expected in 2026. The company's strong financial position, bolstered by a recent public offering, is projected to extend its cash runway into 2029, supporting ongoing pipeline advancement and commercialization preparations.

Management Comments

• "We are incredibly proud of the progress across our entire pipeline this quarter, most notably around our NDA submission for bitopertin in EPP at the end of September and subsequent receipt of the CNPV."
• "Achieving this milestone is a strong testament to our team's commitment to execution and dedication to bringing a potential new treatment option to the EPP patient community."
• "We continue to work with the Agency on their review of our application, and we are furthering our commercial infrastructure in preparation for a potential launch."
• "Beyond bitopertin, our broader pipeline is progressing well, as we expect new data from the Phase 2 trial of DISC-0974 in MF anemia by the end of the year and data from studies of DISC-3405 in PV and SCD next year."
• "With a strong balance sheet providing cash runway into 2029, we are well-positioned to prepare for the anticipated launch of bitopertin and ultimately advancing towards our goal of delivering new treatment options to patients suffering from hematological diseases."

Industry Context

Disc Medicine operates in the highly competitive biopharmaceutical sector, specifically targeting serious hematologic diseases. The submission of an NDA for bitopertin in EPP, a rare disease, positions the company to potentially address an unmet medical need. The receipt of an FDA priority review voucher underscores the potential significance of bitopertin for EPP patients and could accelerate market entry, a critical factor in the drug development industry. The advancement of other pipeline candidates like DISC-0974 and DISC-3405 in areas like myelofibrosis, polycythemia vera, and sickle cell disease indicates a diversified approach within hematology, aiming to capture multiple market segments. The substantial cash runway is crucial for clinical-stage companies to fund lengthy and expensive drug development processes.

Comparison to Industry Standards

• The receipt of an FDA Commissioners National Priority Voucher (CNPV) for bitopertin in EPP is a significant achievement, as these vouchers are awarded for drugs that address rare pediatric diseases or tropical diseases, indicating a high unmet medical need and potential for expedited review, which is a competitive advantage compared to standard review timelines for other drug candidates.
• The extension of the cash runway into 2029 through a public offering provides a longer financial horizon than many clinical-stage biopharmaceutical companies, which often face more frequent capital raises. This extended runway allows for sustained R&D and commercialization efforts without immediate dilution pressure.
• The increase in R&D expenses to $50.3 million in Q3 2025 from $24.7 million in Q3 2024 reflects a typical ramp-up in spending for a clinical-stage company advancing multiple programs, including late-stage development (bitopertin manufacturing) and early-stage trials (DISC-0974, DISC-3405). This level of investment is consistent with companies nearing commercialization while also expanding their pipeline.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress on lead drug candidate (NDA submission, priority review), extended cash runway, and ongoing pipeline development, potentially increasing long-term value. Increased net loss and operating expenses are expected for growth-oriented biopharma.
• Patients (EPP): Highly positive impact with the potential for a new treatment option (bitopertin) and accelerated approval pathway, addressing an unmet medical need.
• Patients (MF, PV, SCD, IBD-anemia): Potential future benefits from ongoing clinical trials of DISC-0974 and DISC-3405, offering hope for new therapies.
• Employees: Increased headcount mentioned for R&D and commercialization infrastructure suggests growth and job security, particularly with the extended cash runway.
• Regulatory Authorities (FDA): Engaged in the review process for bitopertin, with the CNPV indicating a collaborative and expedited pathway.

Next Steps

• FDA review of bitopertin NDA for EPP.
• Further development of commercial infrastructure for bitopertin launch.
• Presentation of initial data from Phase 2 RALLY-MF trial of DISC-0974 at ASH in December.
• Presentation of data from multiple-dose cohorts of Phase 1b study of DISC-0974 in NDD-CKD at ASN Kidney Week.
• Assessment of options for the DISC-0974 program based on full data analysis.
• Initiation of Phase 2 study of DISC-0974 in IBD and anemia in Q1 2026.
• Continuation of Phase 2 study of DISC-3405 in PV.
• Continuation of Phase 1b study of DISC-3405 in SCD.
• Topline data from Phase 2 RALLY-MF trial of DISC-0974 expected in 2026.
• Initial data from Phase 2 study of DISC-3405 in PV expected in 2026.
• Initial data from Phase 1b study of DISC-3405 in SCD expected in 2026.
• Progressing confirmatory Phase 3 APOLLO clinical trial of bitopertin in adults and adolescents with EPP.

Key Dates

Recommendation

The filing details significant de-risking events for Disc Medicine's lead asset, bitopertin, with the NDA submission for EPP and the receipt of an FDA Commissioners National Priority Voucher. This accelerates the potential for market approval and commercialization, which is a major value inflection point for a clinical-stage biopharmaceutical company. The successful public offering, extending the cash runway into 2029, provides substantial financial stability, mitigating near-term dilution concerns and allowing the company to focus on execution. While the company reported an increased net loss and higher operating expenses, these are expected and necessary investments for a company advancing multiple clinical programs and building commercial infrastructure ahead of a potential launch. The overall pipeline progress, despite some mixed results for DISC-0974 in one indication, further supports the long-term growth potential. These factors collectively suggest a strong positive outlook for the stock.

Keywords

Biopharmaceutical, Hematologic Diseases, EPP, Erythropoietic Protoporphyria, Bitopertin, NDA, FDA, CNPV, Myelofibrosis, Anemia, DISC-0974, Polycythemia Vera, Sickle Cell Disease, DISC-3405, Clinical Trials, Q3 2025, Financial Results, Cash Runway, Public Offering, R&D, SG&A, Net Loss